$3.5M grant to help Inovio further develop mass vaccine device

04/11/2013 | Genetic Engineering & Biotechnology News

The National Institute of Allergy and Infectious Diseases awarded Inovio Pharmaceuticals a $3.5 million grant to further develop a next-generation DNA vaccine delivery device that can simultaneously administer multiple synthetic vaccines through skin surface electroporation. The device is being co-developed with Chief Scientist Connie Schmaljohn of the Army Medical Research Institute of Infectious Diseases. The goal is to create a device that will allow fast vaccination of U.S. troops and protect the public from pandemic threats.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ